← Back to home

PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER

Clinical trials for PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER trials appear

Sign up with your email to follow new studies for PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo tested for Tough-to-Treat breast cancer

Disease control Recruiting now

This study is testing whether combining three existing drugs—tucatinib, trastuzumab, and eribulin—is safe and effective for people with advanced HER2+ breast cancer that has continued to grow despite previous treatments. It will enroll about 30 adults to see if this combination c…

Matched conditions: PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER

Phase: PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER

Get alerted when new PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER trials appear

New drug combo tested for Tough-to-Treat breast cancer